{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T05:03:40Z","timestamp":1754111020653},"reference-count":44,"publisher":"Hindawi Limited","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2406,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1600-0404.1985.tb00908.x","type":"journal-article","created":{"date-parts":[[2010,7,24]],"date-time":"2010-07-24T21:44:35Z","timestamp":1280007875000},"page":"506-511","source":"Crossref","is-referenced-by-count":7,"title":["Carbidopa dosage modifies L-DOPA induced side effects and blood levels of L-DOPA and other amino acids in advanced parkinsonism"],"prefix":"10.1155","volume":"72","author":[{"given":"F. Bermejo","family":"Pareja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Martinez-Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Muradas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. G.","family":"Y\u00e9benes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2009,1,29]]},"reference":[{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1007\/BF01485901","article-title":"Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extra-pyramidalen Systems","volume":"38","author":"Ehringer","year":"1960","journal-title":"Wien Klin Wochenschr"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB2|cit2","first-page":"417","article-title":"Levodopa: long-term impact on Parkinson's disease","volume":"1","author":"Anonymous","year":"1981","journal-title":"Br Med J"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB3|cit3","first-page":"77","volume-title":"Current concepts of Parkinson's disease and related disorders","author":"Rinne","year":"1983"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression, and mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000114756","article-title":"Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor","volume":"14","author":"Zumstein","year":"1976","journal-title":"Eur Neurol"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/BF00313615","article-title":"Mortality of patients with Parkinson's disease treated with levodopa","volume":"216","author":"Marttila","year":"1977","journal-title":"J Neurol"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/ana.410030205","article-title":"Levodopa in Parkinson's disease: A long-term appraisal of mortality","volume":"3","author":"Joseph","year":"1978","journal-title":"Ann Neurol"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"456","DOI":"10.7326\/0003-4819-83-4-456","article-title":"Five years' treatment of Parkinson's disease with levodopa","volume":"83","author":"Sweet","year":"1975","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1212\/WNL.29.9_Part_1.1253","article-title":"Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy","volume":"29","author":"Lesser","year":"1979","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/B978-0-407-02295-9.50012-6","volume-title":"Movement disorders","author":"Marsden","year":"1981"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/bmj.3.5777.729","article-title":"Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with Levodopa","volume":"3","author":"Calne","year":"1971","journal-title":"Br Med J"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1212\/WNL.22.4.384","article-title":"Methyldopahydrazine as an adjunct to L-dopa therapy in Parkinsonism","volume":"22","author":"Chase","year":"1972","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1056\/NEJM197201062860102","article-title":"Levodopa in parkinsonism: Potentiation of central effects with a peripheral inhibitor","volume":"285","author":"Papavasilou","year":"1972","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1001\/archneur.1973.00490200039004","article-title":"Modification of levodopa effect by systemic decarboxylase inhibition","volume":"28","author":"Mars","year":"1973","journal-title":"Arch Neurol"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/jnnp.36.1.10","article-title":"Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extra-cerebral DOPA decarboxylase","volume":"36","author":"Marsden","year":"1973","journal-title":"J Neurol Neurosurg Psychiat"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB16|cit16","first-page":"21","volume-title":"Current concepts in the treatment of parkinsonism. (Proceed. 10th Int Congr Neurol)","author":"Marsden","year":"1974"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB17|cit17","first-page":"273","article-title":"R\u00e9sultats apr\u00e8s trois \u00e0 cinq ans de traitement de 219 cas de syndrome parkinsonien trait\u00e9 par la L-Dopa et l'association L-Dopa inhibiteur de la d\u00e9carboxylase","volume":"130","author":"Boudin","year":"1974","journal-title":"Rev Neurol (Paris)"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/archneur.1974.00490380076010","article-title":"Carbidopa in Parkinson's disease and in nausea and vomiting of levodopa","volume":"31","author":"Markham","year":"1974","journal-title":"Arch Neurol"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1212\/WNL.25.10.911","article-title":"Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson's disease","volume":"25","author":"Lieberman","year":"1975","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1212\/WNL.26.5.399","article-title":"Six-year results of treatment with levodopa plus benzerazide in Parkinson's disease","volume":"26","author":"Barbeau","year":"1976","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003495-197611050-00001","article-title":"Levodopa and decarboxylase inhibitors: A review of their clinical pharmacology and use in the treatment of parkinsonism","volume":"11","author":"Pinder","year":"1976","journal-title":"Drugs"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB22|cit22","first-page":"3","article-title":"Carbidopa-levodoterapia (Sinemet) en el tratamiento de enfermos parkinsonianos","volume":"41","author":"Martinez-Lage","year":"1978","journal-title":"Arch Neurobiol (Madrid)"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB23|cit23","first-page":"37","volume-title":"Advances in Neurology, Vol. 2","author":"Porter","year":"1973"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB24|cit24","first-page":"161","volume-title":"Advances in Neurology, Vol. 2","author":"Jaffe","year":"1973"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/archneur.1980.00500520044006","article-title":"Increasing dosage of carbidopa in patients with Parkinson's disease receiving low doses of levodopa. A pilot study","volume":"37","author":"Hoehn","year":"1980","journal-title":"Arch Neurol"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/archneur.1980.00500600071015","article-title":"Increased ratio of carbidopa to levodopa in treatment of Parkinson's disease","volume":"37","author":"Tourtellotte","year":"1980","journal-title":"Arch Neurol"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0022-510X(81)90109-X","article-title":"Classification of extrapyramidal disorders","volume":"51","author":"Ad hoc committee of the research group on extrapyramidal disorders of the World Federation of Neurology","year":"1981","journal-title":"J Neurol Sci"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1365-2125.1981.tb01118.x","article-title":"Assessment of extrapyramidal disorders","volume":"11","author":"Marsden","year":"1981","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.2042-7158.1970.tb10584.x","article-title":"Individual elution of noradrenaline (together with adrenaline), dopamine, 5-hidroxytryptamine and histamine from a single cation echange column by means of mineral and organic solvent mixtures","volume":"22","author":"Atack","year":"1970","journal-title":"J Pharm Pharmacol"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1471-4159.1977.tb07788.x","article-title":"Rapid concurrent automated fluorimetric assay of noradrenaline, dopamine 3,4-dihydroxyphenylacetic acid, homovanillic acid and 3-methoxy-tiramine in milligram amounts of nervous tissue after isolation on Sephadex G-10","volume":"29","author":"Westerink","year":"1977","journal-title":"J Neurochem"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB31|cit31","first-page":"360","article-title":"A study of the factors affecting the aluminium oxide trihydroxyindole procedure for the analysis of catecholamines","volume":"138","author":"Anton","year":"1962","journal-title":"J Pharmacol"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/BF00501936","article-title":"A method for the determination of 3,4-dihydroxyphenilalanine (DOPA) in brain. Naunyn-Schmiedeberg's","volume":"274","author":"Kehr","year":"1972","journal-title":"Arch Pharmacol"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB33|cit33","first-page":"627","article-title":"R\u00e9sultats des dosages de la methoxydopa plasmatique chez les parkinsonisms avec et sans dyskinesies induites par la L-DOPA","volume":"133","author":"Perret","year":"1977","journal-title":"Rev Neurol (Paris)"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB34|cit34","first-page":"733","article-title":"A fluorimetric method for the estimation of tyrosine in plasma and tissue","volume":"50","author":"Waalkes","year":"1957","journal-title":"Lab Clin Med"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00498790","article-title":"Effect of a transverse cerebral hemisection on 5-hydroxytryptamine metabolism in the rat brain","volume":"272","author":"Bedurd","year":"1972","journal-title":"Naunyn-Schmiedeberg's Arch. Pharmacol"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB36|cit36","first-page":"453","article-title":"Treatment of Parkinson's disease with a combination of carbidopa and levodopa (1: 4)","volume":"34","author":"Sotaniemi","year":"1983","journal-title":"Current Therap Res"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB37|cit37","first-page":"101","volume-title":"Treatment of Parkinsonism. The role of DOPA decarboxylase inhibitors. Advances in neurology Vol. 2","author":"Bianchine","year":"1973"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.33.3.278","article-title":"Effects of 3-OM-DOPA on monoamine metabolism in rat brain","volume":"33","author":"Gerv\u00e1s","year":"1983","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB39|cit39","first-page":"259","article-title":"Aspectos farmacocin\u00e9ticos y farmacodin\u00e1micos del tratamiento con L-DOPA m\u00e1s inhibidores de la DDC y agonistas dopamin\u00e9rgicos en la enfermedad de Parkinson","volume":"78","author":"Gerc\u00eda de Y\u00e9benes","year":"1982","journal-title":"Med Clin (Barcelona)"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/ana.410030314","article-title":"A double-blind comparison of levodopa, Madopa, and Sinemet in Parkinson's disease","volume":"3","author":"Diamond","year":"1978","journal-title":"Ann Neurol"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1152\/ajplegacy.1971.221.6.1629","article-title":"Brain uptake of radiolabelled amino acids, amines and hexoses after arterial injection","volume":"221","author":"Oldendorf","year":"1971","journal-title":"Am J Physiol"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ana.410080102","article-title":"Barrier mechanism for neurotransmitter monoamines and their precursors at blood-brain interface","volume":"8","author":"Hardebo","year":"1980","journal-title":"Ann Neurol"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1600-0404.1984.tb07804.x","article-title":"Monoamine metabolites in human cerebrospinal fluid","volume":"69","author":"Mena","year":"1984","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/j.1600-0404.1985.tb00908.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1056\/NEJM198402233100802","article-title":"The \u201con-off\u201d phenomenon in Parkinson's disease: relation to levodopa absorption and transport","volume":"310","author":"Nutt","year":"1984","journal-title":"N Engl J Med"}],"container-title":["Acta Neurologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0404.1985.tb00908.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1600-0404.1985.tb00908.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T12:46:00Z","timestamp":1671540360000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0404.1985.tb00908.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,29]]},"references-count":44,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.1111\/j.1600-0404.1985.tb00908.x","relation":{},"ISSN":["0001-6314","1600-0404"],"issn-type":[{"value":"0001-6314","type":"print"},{"value":"1600-0404","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,29]]}}}